Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 Earnings Yield (Joel Greenblatt) % is 6.65% as of Jun. 2026, which is 2% above its 10-year median of 6.51. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 67.43% on this metric.
Prestige Consumer Healthcare's Enterprise Value for the quarter that ended in Jun. 2026 was $4,218 Mil.
Prestige Consumer Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $280 Mil. Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 6.65%.
The historical rank and industry rank for Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PBH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -0.6 Med: 6.51 Max: 9.34
Current: 6.41
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Prestige Consumer Healthcare was 9.34%. The lowest was -0.60%. And the median was 6.51%.
PBH's Earnings Yield (Joel Greenblatt) % is ranked better than 67.43% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.14
vs PBH: 6.41
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Prestige Consumer Healthcare's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 24.86%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Prestige Consumer Healthcare Earnings Yield (Joel Greenblatt) % Related Terms
Prestige Consumer Healthcare Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Prestige Consumer Healthcares Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Prestige Consumer Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $280 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 6.65% mean?
Prestige Consumer Healthcare (PBH) has a Earnings Yield (Joel Greenblatt) % of 6.65% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Prestige Consumer Healthcare and its competitors. This is near median its historical median of 6.51. According to the industry distribution chart, Prestige Consumer Healthcare ranks #328 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % too high?
Prestige Consumer Healthcare's current Earnings Yield (Joel Greenblatt) % of 6.65% is near median its 10-year median of 6.51. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.14. Prestige Consumer Healthcare's value of 6.65% is 111.8% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #328 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Earnings Yield (Joel Greenblatt) % compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #328 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.14. Prestige Consumer Healthcare's value of 6.65% is 111.8% above this benchmark. While the company's 10-year median is 6.51 vs. the industry median of 3.14, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.14, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Earnings Yield (Joel Greenblatt) % of 6.65% is 111.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Earnings Yield (Joel Greenblatt) % is 6.65%, which is near median its own 10-year median of 6.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 6.65%, which is near median its 10-year median of 6.51 and 111.8% above the Drug Manufacturers industry median of 3.14. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Earnings Yield (Joel Greenblatt) % is 6.65% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
Earnings Yield (Joel Greenblatt) %: 6.65% (near median its 10-year median of 6.51)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 111.8% above the Drug Manufacturers median (#328 of 1007)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
